Not Yet RecruitingNot Applicable

Neurocognitive Assessment in Long-Term Survivors of Lymphoma

Italy100 participantsStarted 2026-09

Plain-language summary

This is an observational, multicenter, prospective cohort study including patients treated for lymphoma in Italian real-life. Patients eligible for the enrollment in the study will be consecutively included in Italian FIL centers. Patients will be evaluated once during regular follow-up, in the absence of clinical or radiologic signs of disease relapse. The assessment of neurocognitive functioning will be performed through a panel of tests, both self-administered and individually administered (about 1 hour). The administration of these neuropsychological tests should be done according to a standardized and predefined order. If available, according to local practice, a neuropsychologist may be involved in test administration and in the evaluation of the results. Based on its observational nature, no treatment change or modification or additional exams or visits will be required because of being enrolled in this study.

Who can participate

Age range

25 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with previous diagnosis of classic Hodgkin Lymphoma (cHL) or Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PMBCL). * Patients in complete remission after first line anthracycline containing regimen (ABVD, BV-AVD, BEACOPP, R-CHOP, Pola-R-CHP o R-DA-EPOCH) +/- radiotherapy. * Age ≥ 25 and ≤ 55 at enrollment. * Patients between third and fifth year of follow-up after the end of the first line treatment. * Absence of signs or symptoms of disease relapse. Exclusion Criteria: * Patients with CNS disease localization. * Patients that received brain/neuroaxis radiotherapy. * Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This study is focused on long-term survivors of lymphomas like Hodgkin lymphoma and DLBCL — given my specific diagnosis and the treatment I've had or am planning, does my doctor think I could be a good fit to discuss once this trial opens for recruitment?
2The trial is measuring a wide range of brain functions — memory, language, attention, and executive skills — using tests like the Rey Auditory Verbal Learning Test and the Trail Making Test. Can my doctor explain whether any of my treatments, like anthracyclines, radiation, or CNS prophylaxis, are known to affect these specific cognitive areas?
3Since this study is not yet recruiting, what neurocognitive monitoring or support is available to me right now as a lymphoma patient or survivor, without waiting for this trial to begin?
4The trial is tracking prior radiotherapy field and dose as part of what it's measuring — should I be asking my care team to document these treatment details carefully now, so they're available if I later want to participate in this or a similar observational study?
5This appears to be an observational study rather than a treatment trial — can my doctor help me understand what participating would actually involve in terms of visits, time commitment, and cognitive testing, and whether it would run alongside or separately from my regular follow-up care?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Self-assessed neurocognitive performance

Timeframe: The endpoint will be evaluated only once after screening and signing of informed consent form (Day 1)

Neurocognitive performance evaluation: Cognitive Status - Mini-Mental State Examination (MMSE)

Timeframe: The endpoint will be evaluated only once after screening and signing of informed consent form (Day 1)

Neurocognitive performance evaluation: Language - Verbal Fluency Test (Phonemic and semanthic)

Timeframe: The endpoint will be evaluated only once after screening and signing of informed consent form (Day 1)

Neurocognitive performance evaluation: Language - Naming of colored Photographs

Timeframe: The endpoint will be evaluated only once after screening and signing of informed consent form (Day 1)

Neurocognitive performance evaluation: Verbal Memory - Digit Span Test (Forward, Backward)

Timeframe: The endpoint will be evaluated only once after screening and signing of informed consent form (Day 1)

Neurocognitive performance evaluation: Verbal Memory - Rey Auditory Verbal Learning Test (Word List 3 Recall)

Trial details

NCT IDNCT07652476

SponsorFondazione Italiana Linfomi - ETS

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-03

Contact for this trial

Iolanda Uffici Studi FIL

+390131033153 startup@filinf.it

View on ClinicalTrials.gov More Classic Hodgkin Lymphoma trials